IRR is a thriving hub for innovation, providing an excellent environment for spinout companies to flourish and accelerate real-world impact. We are home to a vibrant community of talented researchers and industry professionals, offering a wealth of opportunities for collaboration. We are further supported by an experienced team at Edinburgh Innovations, the University of Edinburgh’s commercialisation service, that provide guidance on translational opportunities. Our cutting-edge facilities and close proximity to patients at the the Royal Infirmary of Edinburgh and clinical trials facilities, are fundamental to accelerating the development of effective new therapies. Resolution Therapeutics Inflammatory and fibrotic diseases affect millions of patients worldwide. Resolution therapeutics aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.Read more on our websiteFounder/Co-founder: Professor Stuart Forbes Forth Therapeutics Forth therapeutics is pioneering precision therapeutics that target the underlying mechanisms driving fibrosis. Building on world-renowned research, they are leveraging multi-omic insights from patient-derived tissue samples to develop potent, new therapies for patients.Read more on our websiteFounder/Co-founder: Professor Neil Henderson Trogenix Through their proprietary gene therapy platform, Odysseus®, Trogenix is uniquely positioned to develop precision cancer treatments that selectively target diseased cell states and behaviour, combining payloads that reveal cancer to the body’s immune system and kill tumour cells.Read more on our websiteFounder/Co-founder: Professor Steven Pollard Prothea Technologies The biopsy and treatment of lung cancer in a single hospital visit – reducing time-to-treat from weeks to minutes; relieving hospital pressures, improving patient outcomes.Read more on our websiteFounder/Co-founder: Professor Kev Dhaliwal Kynos Therapeutics / Dr. Falk Pharma Kynos Therapeutics developed a lead drug candidate which plays a major role in the regulation of inflammation. In October 2024, Kynos Therapeutics was acquired by Dr Falk Pharma , which will continue development of Kynos’ drug candidate for the treatment of acute pancreatitis.Read more on our websiteFounder/Co-founder: Damian Mole This article was published on 2026-02-05
